Comparing PetVivo (NASDAQ:PETV) and Nyxoah (NASDAQ:NYXH)

Nyxoah (NASDAQ:NYXH) and PetVivo (NASDAQ:PETV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.

Valuation & Earnings

This table compares Nyxoah and PetVivo”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$4.79 million	49.96	-$46.77 million	($1.64)	-5.85
PetVivo	$970,000.00	11.58	-$10.95 million	($0.65)	-0.86

PetVivo has lower revenue, but higher earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than PetVivo, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Nyxoah and PetVivo, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	0	0	5	0	3.00
PetVivo	0	0	0	0	N/A

Nyxoah presently has a consensus target price of $17.00, indicating a potential upside of 77.08%. Given Nyxoah’s higher probable upside, analysts clearly believe Nyxoah is more favorable than PetVivo.

Risk and Volatility

Nyxoah has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500. Comparatively, PetVivo has a beta of 2.51, indicating that its stock price is 151% more volatile than the S&P 500.

Profitability

This table compares Nyxoah and PetVivo’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nyxoah	-908.32%	-42.00%	-33.43%
PetVivo	-1,036.82%	-1,038.50%	-266.37%

Insider & Institutional Ownership

24.6% of PetVivo shares are owned by institutional investors. 17.1% of Nyxoah shares are owned by insiders. Comparatively, 20.1% of PetVivo shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Nyxoah beats PetVivo on 7 of the 12 factors compared between the two stocks.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

About PetVivo

PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.